Syros Pharmaceuticals, Inc. – common stock(NASDAQ:SYRS) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 20, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.47. The reported EPS was above estimates by 26.56%. Analysts had estimated an EPS of $-0.64.
Syros Pharmaceuticals, Inc. – common stock (SYRS) made into the market gainers list on Wednesdays trading session with the shares advancing 1.23% or 0.18 points. Due to strong positive momentum, the stock ended at $14.82, which is also near the day’s high of $14.99. The stock began the session at $14.55 and the volume stood at 17,940 shares. The 52-week high of the shares is $21.5 and the 52 week low is $8.16. The company has a current market capitalization of $347 M and it has 2,33,92,918 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 7, 2016, Amir Nashat (director 10% owner) purchased 400,000 shares at $12.50 per share price.Also, On Jul 6, 2016, Robert Nelsen (director 10% owner) purchased 400,000 shares at $12.50 per share price.